May 04, 2018


New EAS Consensus Panel Statement on Statin Safety

EAS Consensus panel addresses persistent questions on long-term statin safety in a new Consensus paper published in the European Heart Journal on April 27.

This joint consensus statement from the European Society of Cardiology and the European Atherosclerosis Society Task Force has Open Access and you will find the paper in full at the EAS web together with the editorial "EAS Consensus panel answers the questions on statin safety" by Scientific writer Jane K. Stock and accompanying slides.

A summary of the joint consensus statement will be presented for the first time in a "Breaking News" session at EAS 2018 Lisbon on Monday 07 May 15:45.

To the EAS 2018 programme on the web.

To the Consensus Paper, Editorial and Slideset >>


Journal highlights April

In our regular feature, Editor-in-Chief Arnold von Eckardstein highlights interesting articles from recent issues of Atherosclerosis journal.

Diabetes and obesity are prevalent in many populations and contribute to the increasing burden of atherosclerotic cardiovascular diseases (ASCVD). However, there is considerable heterogeneity in the manifestation of ASCVD among obese and diabetic subjects. The April issue of Atherosclerosis, Volume 271, contains several reviews and original articles, which describe possible pathogenic reasons for the inter-individual differences in risk as well as strategies to differentiate risk for more specific interventions. In addition, preclinical and clinical intervention studies are described.

To the journal highlights April >>

To the April issue of Atherosclerosis >>


Editorial "At the end of the ODYSSEY…what now for PCSK9 inhibition in practice?"

In March, the second of the cardiovascular outcomes studies with a PCSK9 inhibitor reported, showing significant clinical benefit in patients with acute coronary syndromes. This commentary discusses these findings in context and considers the implications for clinicians, guideline groups and payers. Read the editorial by EAS Scientific writer Jane Stock.

"At the end of the ODYSSEY…what now for PCSK9 inhibition in practice?" >>


EAS Advanded Courses 2018

EAS aims to promote education and training in the prevention and care of atherosclerosis and its clinical manifestations, and equally in basic science, in the atherosclerosis field. To fulfill this aim the Society runs a programme of Advanced Courses.

The courses each highlight a different aspect of basic science and research or clinical prevention, diagnosis and treatment in the field of atherosclerotic vascular disease and its complications, including myocardial infarction, cerebro- and peripheral vascular disease. The courses are run by recognized experts and distinguished specialists in the relevant research or clinical area, and are held in established centres of excellence throughout Europe.

Autumn courses 2018

  • EAS Advanced Course on Epidemiology and genetics of atherosclerosis and causality of risk factors
    October 10-12, 2018 in Copenhagen, Denmark

  • EAS Advanced Course in Clinical Excellence in Lipidology - from risk to prevention
    November 22-23, 2018 in Bucharest, Romania

  • EAS Advanced Course in Atherosclerosis at the interface of hyperlipidemia and inflammation
    December 2018 in Vienna, Austria



Application to these courses will open early summer - please check our web for updates.

Lectures from previous Advanced Courses are available as webcasts on EAS Academy.

  Read more about EAS Advanced Courses >>

Read the evaluations on EAS courses held >>

Find out more

About EAS

EAS Membership

EAS Congress

EAS Educational Initiatives

EAS Publications

European Lipoprotein Club (ELC)

EAS-FH Studies Collaboration (FHSC)


About this email

You have received this email because you are currently subscribed to receive general correspondence from EAS.


European Atherosclerosis Society
Mässans Gata 18
Box 5243
SE-402 24, Gothenburg SWEDEN

Organisation number: 802418-0427

This email was sent to '@@email@@' from European Atherosclerosis Society.
If you wish to stop receiving email from us, you can simply remove yourself by visiting: @@unsubscribe_url@@


European Atherosclerosis Society © 2018